N-(3-chloro-4-fluorobenzyl)-2-amino-5-nitrobenzamide | 1071463-63-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-chloro-4-fluorobenzyl)-2-amino-5-nitrobenzamide
• 英文别名: 2-amino-N-[(3-chloro-4-fluorophenyl)methyl]-5-nitrobenzamide
• CAS: 1071463-63-2
• 化学式: C₁₄H₁₁ClFN₃O₃
• 分子量: 323.711
• InChiKey: TWBNPIFGWXATFS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(3-chloro-4-fluorobenzyl)-2-amino-5-nitrobenzamide 、 原甲酸三乙酯 反应 24.0h， 生成 3-(3-chloro-4-fluorobenzyl)-6-nitroquinazolin-4-(3H)-one
  参考文献：
  名称：

  Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors

  摘要：

  We discovered a structurally novel SCD (Delta 9 desaturase) inhibitor 4a (CVT-11,563) that has 119 nM potency in a human cell-based (HEPG2) SCD assay and selectivity against Delta 5 and Delta 6 desaturases. This compound has 90% oral bioavailability (rat) and excellent plasma exposure (dAUC 935 ng h/mL). Additionally, 4a shows moderately selective liver distribution (three times vs plasma and adipose tissue) and relatively low brain penetration. In a five-day study (high sucrose diet, rat) compound 4a significantly reduced SCD activity as determined by GC analysis of fatty acid composition in plasma and liver. We describe the discovery of 4a from HTS hit 1 followed by scaffold replacement and SAR studies focused on DMPK properties. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.004
• 作为产物：
  描述：

  2-氨基-5-硝基苯甲酸 、 3-氯-4-氟苄胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 氯仿 为溶剂， 生成 N-(3-chloro-4-fluorobenzyl)-2-amino-5-nitrobenzamide
  参考文献：
  名称：

  Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors

  摘要：

  We discovered a structurally novel SCD (Delta 9 desaturase) inhibitor 4a (CVT-11,563) that has 119 nM potency in a human cell-based (HEPG2) SCD assay and selectivity against Delta 5 and Delta 6 desaturases. This compound has 90% oral bioavailability (rat) and excellent plasma exposure (dAUC 935 ng h/mL). Additionally, 4a shows moderately selective liver distribution (three times vs plasma and adipose tissue) and relatively low brain penetration. In a five-day study (high sucrose diet, rat) compound 4a significantly reduced SCD activity as determined by GC analysis of fatty acid composition in plasma and liver. We describe the discovery of 4a from HTS hit 1 followed by scaffold replacement and SAR studies focused on DMPK properties. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.004

文献信息

• 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
  申请人：Koltun Dmitry

  公开号：US20080255161A1

  公开（公告）日：2008-10-16

  The present invention discloses 3-hydroquinazolin-4-one derivatives for use as inhibitors of stearoyl-CoA desaturase. The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cancer, cardiovascular disease, diabetes, obesity, metabolic syndrome and the like.

  本发明揭示了3-羟基喹唑啉-4-酮衍生物，用作硬脂酰辅酶A去饱和酶的抑制剂。这些化合物在治疗和/或预防由硬脂酰辅酶A去饱和酶（SCD）酶介导的各种人类疾病方面具有用途，特别是与异常脂质水平、癌症、心血管疾病、糖尿病、肥胖、代谢综合征等相关的疾病。